Literature DB >> 7928373

The production of dialysis by for-profit versus not-for-profit freestanding renal dialysis facilities.

R I Griffiths1, N R Powe, D J Gaskin, G F Anderson, G V de Lissovoy, P K Whelton.   

Abstract

OBJECTIVE: A study was conducted to determine whether for-profit and not-for-profit freestanding renal dialysis facilities differ with respect to efficiency in the production of dialysis treatments. DATA SOURCES/STUDY
SETTING: National data on 1,224 Medicare-certified freestanding dialysis facilities were obtained from the Health Care Financing Administration's (HCFA) 1990 Independent Renal Dialysis Facility Cost Report. Data on Medicare patients receiving care at these facilities during 1990 were obtained from HCFA's End Stage Renal Disease (ESRD) Program Management and Medical Information System (PMMIS). STUDY
DESIGN: Ordinary least squares regression (OLS) was used to estimate the association between monthly output of dialysis treatments in 1990 and (a) facility capital and labor inputs, (b) facility ownership characteristics, and (c) case-mix characteristics. DATA COLLECTION/EXTRACTION
METHODS: Facility and patient level data were extracted from the Facility Cost Report and the PMMIS databases, respectively. Patient level data were aggregated by facility and merged with facility level data. PRINCIPAL
FINDINGS: For-profit sole proprietorships, for-profit partnerships and for-profit corporations each produced significantly more dialysis treatments per month than not-for-profits, adjusting for quantities of resource inputs and case-mix characteristics.
CONCLUSION: For-profit facilities appear to be more efficient producers of dialysis treatments than not-for-profits. Further study should address whether other factors such as differences in severity of disease or in quality of care are responsible for these observations.

Entities:  

Mesh:

Year:  1994        PMID: 7928373      PMCID: PMC1070018     

Source DB:  PubMed          Journal:  Health Serv Res        ISSN: 0017-9124            Impact factor:   3.402


  10 in total

1.  The Medicare cost of renal dialysis. Evidence from a statistical cost function.

Authors:  A Dor; P J Held; M V Pauly
Journal:  Med Care       Date:  1992-10       Impact factor: 2.983

2.  The production and cost of ambulatory medical care in community health centers.

Authors:  F Goldman; M Grossman
Journal:  Adv Health Econ Health Serv Res       Date:  1983

3.  Investor-owned hospitals and health-care costs.

Authors:  A S Relman
Journal:  N Engl J Med       Date:  1983-08-11       Impact factor: 91.245

4.  Profit and the end-stage renal-disease program.

Authors:  K D Gardner
Journal:  N Engl J Med       Date:  1981-08-20       Impact factor: 91.245

5.  Case mix in end-stage renal disease. Differences between patients in hospital-based and free-standing treatment facilities.

Authors:  A L Plough; S R Salem; M Shwartz; J M Weller; C W Ferguson
Journal:  N Engl J Med       Date:  1984-05-31       Impact factor: 91.245

6.  Survival analysis of patients undergoing dialysis.

Authors:  P J Held; M V Pauly; L Diamond
Journal:  JAMA       Date:  1987-02-06       Impact factor: 56.272

7.  Competition and efficiency in the end stage renal disease program.

Authors:  P J Held; M V Pauly
Journal:  J Health Econ       Date:  1983-08       Impact factor: 3.883

8.  The excess incidence of diabetic end-stage renal disease among blacks. A population-based study of potential explanatory factors.

Authors:  F L Brancati; J C Whittle; P K Whelton; A J Seidler; M J Klag
Journal:  JAMA       Date:  1992-12-02       Impact factor: 56.272

9.  The success of medicare's end-stage renal-disease program: the case for profits and the private marketplace.

Authors:  E G Lowrie; C L Hampers
Journal:  N Engl J Med       Date:  1981-08-20       Impact factor: 91.245

10.  End-stage renal disease: a profile of facilities furnishing treatment.

Authors:  D Gibson; M McMullan
Journal:  Health Care Financ Rev       Date:  1984
  10 in total
  13 in total

1.  A national study of efficiency for dialysis centers: an examination of market competition and facility characteristics for production of multiple dialysis outputs.

Authors:  Hacer Ozgen; Yasar A Ozcan
Journal:  Health Serv Res       Date:  2002-06       Impact factor: 3.402

2.  Longitudinal analysis of efficiency in multiple output dialysis markets.

Authors:  Hacer Ozgen; Yasar A Ozcan
Journal:  Health Care Manag Sci       Date:  2004-11

3.  Predictors of chain acquisition among independent dialysis facilities.

Authors:  Alyssa S Pozniak; Richard A Hirth; Jane Banaszak-Holl; John R C Wheeler
Journal:  Health Serv Res       Date:  2010-02-09       Impact factor: 3.402

4.  For-profit status and industry evolution in health care markets: evidence from the dialysis industry.

Authors:  Nathan E Wilson
Journal:  Int J Health Econ Manag       Date:  2016-07-14

5.  Patients, populations and policy: patient outcomes in chronic kidney disease.

Authors:  N R Powe
Journal:  Trans Am Clin Climatol Assoc       Date:  2001

6.  The effect of dialysis chains on mortality among patients receiving hemodialysis.

Authors:  Yi Zhang; Dennis J Cotter; Mae Thamer
Journal:  Health Serv Res       Date:  2010-12-09       Impact factor: 3.402

7.  Practice patterns, case mix, Medicare payment policy, and dialysis facility costs.

Authors:  R A Hirth; P J Held; S M Orzol; A Dor
Journal:  Health Serv Res       Date:  1999-02       Impact factor: 3.402

8.  Variation in dialysis quality measures by facility, neighborhood, and region.

Authors:  Milda R Saunders; Marshall H Chin
Journal:  Med Care       Date:  2013-05       Impact factor: 2.983

9.  Comparison of hospitalization rates among for-profit and nonprofit dialysis facilities.

Authors:  Lorien S Dalrymple; Kirsten L Johansen; Patrick S Romano; Glenn M Chertow; Yi Mu; Julie H Ishida; Barbara Grimes; George A Kaysen; Danh V Nguyen
Journal:  Clin J Am Soc Nephrol       Date:  2013-12-26       Impact factor: 8.237

10.  A 12-year analysis of Malmquist total factor productivity in dialysis facilities.

Authors:  Nick Kontodimopoulos; Dimitris Niakas
Journal:  J Med Syst       Date:  2006-10       Impact factor: 4.920

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.